In vitro propagation of embryonic stem cells

• US 7,186,883 B2
• Filed: 04/12/2002
• Issued: 03/06/2007
• Est. Priority Date: 08/04/1988
• Status: Expired due to Fees

• Current Assignee: Zenyth Operations Pty. Ltd.
• Original Assignee: Zenyth Operations Pty. Ltd.
• Inventors: Hilton, Douglas James, Gough, Nicholas Martin, Williams, Robert Lindsay
• Primary Examiner(s): WOITACH, JOSEPH T
• Application Number:
  US10/121,220
• Publication Number:
  US 20030064512A1
• Time in Patent Office: 1,789 Days
• Field of Search: 800/18
• US Class Current: 800/21
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

Abstract

The present invention relates to the use of leukemia inhibitory factor (LIF) in the isolation and propagation of embryonic stem cells in vitro.

Claims

1. A method of producing a genetically modified mouse, comprising culturing murine embryonic stem (ES) cells in culture medium containing an effective amount of recombinant leukaemia inhibitory factor under conditions sufficient to maintain said ES cells and producing a genetically modified mouse using said ES cells.

3. The method according to claim 1 or claim 2, further comprising isolating said ES cells and producing said genetically modified mouse from said isolated ES cells.

4. The method according to claim 1 or claim 2 wherein the culture medium is free of feeder cells.

5. The method according to claim 1 or claim 2 wherein said leukaemia inhibitory factor is recombinant human or murine leukaemia inhibitory factor.

6. The method according to claim 1 or claim 2, further comprising producing progeny from said genetically modified mouse wherein said progeny comprises the genetic modification of said genetically modified mouse.

2. A method of producing a genetically modified mouse, comprising culturing murine embryos in vitro in culture medium containing an effective amount of recombinant leukaemia inhibitory factor for an effective time and under conditions sufficient for the development of embryonic stem (ES) cells and producing a genetically modified mouse using said ES cells.